Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

6.910 +0.080 (+1.17%)
Streaming Delayed Price Updated: 10:26 AM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Compass (CMPS) Q2 Loss Improves 27%
Via The Motley Fool
Earnings Scheduled For July 31, 2025
 
Via Benzinga
These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy?
Via The Motley Fool
Stifel Says Compass Pathways Selloff 'Significantly Overdone' After Psilocybin Trial Data
The company is also conducting a second Phase 3 study evaluating the effects of two doses of COMP360 given three weeks apart. 
Via Stocktwits
What's going on in today's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Earnings Scheduled For February 27, 2025
 
Via Benzinga
Compass Pathways Stock Is Plunging Today: What's Going On?
COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial, but results may have not met lofty... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts
The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it. 
Via Stocktwits
Crude Oil Falls 1%; US Services PMI Declines In June
 
Via Benzinga
Which stocks are experiencing notable movement on Monday?
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Why Is Compass Pathways Stock Trading Lower On Monday?
Compass Pathways' COMP005 trial met its primary endpoint in TRD, but modest results sparked a 47% drop in shares amid investor disappointment 
Via Benzinga
Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results
 
Via Benzinga
Topics Stocks
These stocks are gapping in today's session
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
These stocks are moving in today's pre-market session
Discover the top movers in Monday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Sequans Communications Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more. 
Via Benzinga
Topics Government
Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Why Compass Pathways Stock Was a Double-Digit Winner This Week
Via The Motley Fool
Mind Medicine's Net Losses Swell In Q4, But Retail Finds At Least 3 Reasons To Stay Bullish
The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier. 
Via Stocktwits
Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026. 
Via Benzinga
Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript
CMPS earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
This Plumas Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
 
Via Benzinga
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months
Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca. 
Via Stocktwits
RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.
The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.